Clinical Trial Detail

NCT ID NCT02073487
Title Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab With Lapatinib and Paclitaxel
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements yes
Sponsors The Methodist Hospital System
Indications

Her2-receptor positive breast cancer

Therapies

Paclitaxel

Trastuzumab emtansine + Lapatinib

Trastuzumab + Lapatinib

nab-paclitaxel

Age Groups: adult

Additional content available in CKB BOOST